Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy

Introduction: HTX-019 (CINVANTI(®)) is a novel injectable emulsion formulation of the neurokinin 1 receptor antagonist (RA) aprepitant, approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 has demonstrated a tolerable safety profile when administered via...

Descripción completa

Detalles Bibliográficos
Autores principales: Navari, Rudolph M, Mosier, Michael C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503333/
https://www.ncbi.nlm.nih.gov/pubmed/31118678
http://dx.doi.org/10.2147/OTT.S201609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503333/
https://www.ncbi.nlm.nih.gov/pubmed/31118678
http://dx.doi.org/10.2147/OTT.S201609

Ejemplares similares